Fertility of Tall Girls Treated With High-Dose Estrogen, A Dose-Response Relationship

2013 ◽  
Vol 68 (1) ◽  
pp. 36-37
Author(s):  
A. E. J. Hendriks ◽  
S. L. S. Drop ◽  
J. S. E. Laven ◽  
A. M. Boot
Keyword(s):  
Dose Response ◽  
High Dose ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Tall Girls

scholarly journals Fertility of Tall Girls Treated with High-Dose Estrogen, a Dose-Response Relationship

2012 ◽  
Vol 97 (9) ◽  
pp. 3107-3114 ◽  
Author(s):  
A. E. J. Hendriks ◽  
S. L. S. Drop ◽  
J. S. E. Laven ◽  
A. M. Boot
Keyword(s):  
Dose Response ◽  
High Dose ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Tall Girls

scholarly journals Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma

2019 ◽  
Vol 55 (1) ◽  
pp. 1901147 ◽  
Author(s):  
Ingrid Maijers ◽  
Nethmi Kearns ◽  
James Harper ◽  
Mark Weatherall ◽  
Richard Beasley
Keyword(s):  
Dose Response ◽  
Oral Corticosteroid ◽  
Inhaled Corticosteroids ◽  
Adrenal Suppression ◽  
Oral Steroid ◽  
Systemic Effects ◽  
High Dose ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Sparing Effect

BackgroundThe proportion of the efficacy of high-dose inhaled corticosteroids (ICS) in oral corticosteroid-dependent asthma that is due to systemic effects is uncertain. This study aimed to estimate the ICS dose–response relationship for oral corticosteroid-sparing effects in oral corticosteroid-dependent asthma, and to determine the proportion of oral corticosteroid-sparing effects due to their systemic effects, based on the comparative dose–response relationship of ICS versus oral corticosteroids on adrenal suppression.MethodsSystematic review and meta-analysis of randomised controlled trials reporting oral corticosteroid-sparing effects of high-dose ICS in oral corticosteroid-dependent asthma. In addition, reports of oral corticosteroid to ICS dose-equivalence in terms of adrenal suppression were retrieved. The primary outcome was the proportion of the oral corticosteroid-sparing effect of ICS that could be attributed to systemic absorption, per 1000 µg increase of ICS, expressed as a ratio. This ratio estimates the oral corticosteroid sparing effect of ICS due to systemic effects.Results11 studies including 1283 participants reporting oral corticosteroid-sparing effects of ICS were identified. The prednisone dose decrease per 1000 µg increase in ICS varied from 2.1 mg to 4.9 mg, depending on the type of ICS. The ratio of the prednisone-sparing effect due to the systemic effects per 1000 µg of fluticasone propionate was 1.02 (95% CI 0.68–2.08) and for budesonide was 0.93 (95% CI 0.63–1.89).ConclusionIn patients with oral corticosteroid-dependent asthma, the limited available evidence suggests that the majority of the oral corticosteroid-sparing effect of high-dose ICS is likely to be due to systemic effects.

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4722-4722
Author(s):  
Casey A. Moffa ◽  
Chandana Thatikonda ◽  
Neeta Pathe ◽  
James M. Rossetti ◽  
Richard K. Shadduck ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Dose Response ◽  
Combination Chemotherapy ◽  
Progressive Disease ◽  
Standard Dose ◽  
Absolute Lymphocyte Count ◽  
High Dose ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Final Treatment

Abstract Background: Rituximab at standard dose (375 mg/m2) in combination with chemotherapy has been used to treat CLL and NHL. We retrospectively evaluated the response and toxicity of high dose rituximab (HDR) (500 mg/m2 thrice weekly for 2 weeks, total dose 3 gm/m2) in patients with CLL or NHL, who had received prior treatment with standard rituximab as either monotherapy or in combination chemotherapy, to determine if there was a dose response relationship. Methods: Eight patients with either CLL or NHL who had received HDR therapy were evaluated. Patients received HDR because they refused conventional treatment or failed to respond to prior combination chemotherapy. Seven of the patients had prior combination therapy, whereas 1 had received standard dose rituximab alone. Response to HDR was evaluated based upon absolute lymphocyte count approximately 21 days after the final treatment in CLL patients and PET/CT scan after the final treatment for NHL. Results: Mean age at treatment: 70 yrs (range = 57–83), males (n=7) and female (n=1), CLL (n=5) and NHL (n=3). One patient with CLL had Richter’s transformation. Patients received prior treatments with rituxan alone (n=1), combination therapy for CLL with FCR, FR or PCR (n=5) or combination therapy for NHL with hyperCVAD-R, CHOP-R or RICE (n=2). Of the 5 patients with CLL treated with HDR, 3 achieved partial remission (PR) while the remaining 2 patients developed progressive disease. Complete remission, however, could not be assessed secondary to lack of a post treatment bone marrow biopsy. All 3 patients with NHL developed progressive disease. One patient developed rigors during the infusion of HDR requiring IV steroids. No infusion was stopped secondary to toxicity. Conclusions: Based upon our findings, HDR was active in patients with relapsed CLL but not in relapsed NHL. Further exploration of this dose-response relationship is warranted in patients with CLL.

scholarly journals Nonlinear Dose-Response Relationship in the Immune System following Exposure to Ionizing Radiation: Mechanisms and Implications

2003 ◽  
Vol 1 (1) ◽  
pp. 154014203908444 ◽  
Author(s):  
Shu-Zheng Liu
Keyword(s):  
T Lymphocyte ◽  
Dose Response ◽  
Low Dose ◽  
Cell Types ◽  
High Dose ◽  
Response Relationship ◽  
Low Dose Radiation ◽  
Dose Response Relationship ◽  
Dose Radiation ◽  
Different Doses

The health effects of low-dose radiation (LDR) have been the concern of the academic spheres, regulatory bodies, governments, and the public. Among these effects, the most important is carcinogenesis. In view of the importance of immune surveillance in cancer control, the dose-response relationship of the changes in different cell types of the immune system after whole-body irradiation is analyzed on the basis of systemic data from the author's laboratory in combination with recent reports in the literature. For T lymphocytes J- or inverted J-shaped curves are usually demonstrated after irradiation, while for macrophages dose-response curves of chiefly stimulation with irregular patterns are often observed. The intercellular reactions between the antigen presenting cell (APC) and T lymphocyte (TLC) in the immunologic synapse via expression of surface molecules and secretion of cytokines by the two cell types after different doses of radiation are illustrated. The different pathways of signal transduction thus facilitated in the T lymphocyte by different doses of radiation are analyzed to explain the mechanism of the phenomenon of low-dose stimulation and high-dose suppression of immunity. Experimental and clinical data are cited to show that LDR retards tumor growth, reduces metastasis, increases the efficacy of conventional radiotherapy and chemotherapy as well as alleviates the suppression of immunity due to tumor burden. The incidence of thymic lymphoma after high-dose radiation is lowered by preexposure to low-dose radiation, and its mechanism is supposed to be related to the stimulation of anticancer immunity induced by low-dose radiation. Recent reports on lowering of standardized cancer mortality rate and all cause death rate of cohorts occupationally exposed to low-dose radiation from the US, UK, and Canada are cited.

Comparison of Patiromer to Sodium Polystyrene Sulfonate in Acute Hyperkalemia

2021 ◽  
pp. 001857872110375
Author(s):  
Peter T. Nguyen ◽  
Vivek K. Kataria ◽  
Teena R. Sam ◽  
Katie Hooper ◽  
Ankit N. Mehta
Keyword(s):  
Dose Response ◽  
Linear Regression Analysis ◽  
High Dose ◽  
Sodium Polystyrene Sulfonate ◽  
Polystyrene Sulfonate ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Improvement Project ◽  
Transplant Patients ◽  
Clinically Significant

Background: Patiromer and sodium polystyrene sulfonate (SPS) are cation-exchangers approved for the treatment of chronic hyperkalemia. Data regarding their efficacy acutely is lacking. Despite this, both drugs are frequently used in the emergent setting. Objective: The purpose of this study was to compare the potassium reduction of patiromer to SPS within 6 to 24 hours following a single dose. Methods: This retrospective quality improvement project included hyperkalemic patients receiving 1 dose of patiromer or SPS and had a second potassium level drawn in 6 to 24 hours. Doses of 8.4 g of patiromer and 15 g of SPS were considered “low dose” while 16.8 g of patiromer and 30 g of SPS were considered “high dose.” The presence of a dose-response relationship was assessed through a linear regression analysis. Results: Mean (SD) potassium reduction was higher in SPS than patiromer [0.76 (0.63) mEq/L vs 0.32 (0.65) mEq/L, ( P = .001)]. A dose response relationship was not demonstrated in low versus high dose groups [−0.21 (0.14), P = .13] and CKD, ESRD, and renal transplant patients when compared to patients with normal renal function [0.11 (0.17), P = .51, −0.07 (0.19), P = −0.07 (0.19), P = .73, and −0.10 (0.22), P = .65]. Conclusions: This study suggests a clinically significant reduction in potassium with SPS compared to patiromer. Although SPS was successful in demonstrating this outcome, due to well-documented adverse reactions in the literature and a time to onset of 6 hours, it cannot be recommended for use in acute hyperkalemia either.

Sign in / Sign up

Export Citation Format

Share Document